OOIR: Observatory of International Research

Papers

(The H4-Index of Research and Practice in Thrombosis and Haemostasis is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Reevaluating thromboprophylaxis in COVID-19 outpatients: the case for a targeted, risk-based approach	80
Navigating the inevitable: artificial intelligence and the future of scientific communication	79
Do combined oral contraceptives induce formation of tissue factor?	71
Erratum to ‘A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays.’ [Research and Practice in Thrombosis and Haemostasis Vo	65
Performance of risk scores in predicting major bleeding in left ventricular assist device recipients: a comparative external validation	51
Corrigendum to ‘Optimizing care for patients after major anticoagulant-related bleeding: a narrative review and proposal for a clinical care pathway’	47
How do anticoagulants impact menstrual bleeding and quality of life? - The PERIOD study	44
Daratumumab in relapse-refractory immune-mediated thrombotic thrombocytopenic purpura: additional evidence for its efficacy	43
Analytical validity of the INNOVANCE Antithrombin assay for the measurement of antithrombin activity at fitusiran clinical decision points	38
Rare inherited coagulation disorders: no longer orphan and neglected	38
140 Impact of Amiodarone Exposure on Apixaban Pharmacokinetics in Hospitalized Patients	37
141 Heparin Management - The Ultimate Goldilocks Dilemma: A Quality Improvement Project	36
128 Evaluation of Heparin-Induced Thrombocytopenia Testing to Improve Anticoagulation Stewardship in an Acute Care Setting	36
84 Rural Improvements in Venous Thrombosis Treatment in Oklahoma: The RIVETT-OK Initiative	34
Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality	33
Intraindividual variability of von Willebrand factor and the need for repeated testing	32
Von Willebrand disease diagnosis: from complexity to simplicity	32
Thrombophilia and outcomes of venous thromboembolism in older patients	32
Contemporary trends in maternal outcomes during delivery hospitalizations among pregnancies complicated by von Willebrand disease—a cross-sectional analysis	27
HTRS2025.P1.8 Efanesoctocog Alfa for the Perioperative Management of Patients With Severe Hemophilia A: 4 Years of Experience in the XTEND Clinical Program in North America	27
Promise and pitfalls of viscoelastic testing for assessing blood hemostasis in ultraendurance sports	27
Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany	27
Acquired von Willebrand syndrome in children	27
HTRS2025.P1.29 Factors Associated with Disseminated Intravascular Coagulation in non-APL Acute Myeloid Leukemia	26
HTRS2025.O8A.6 The heme-induced mitochondrial oxidant-dependent platelet secretome promotes endothelial dysfunction	25